TLX Pre-Biopsy NDA Opens 3x Bigger PSMA-PET Market

The market read Telix’s September 2 announcement the wrong way. When a company says “enrollment complete” and “we aligned with the FDA on a pathway,” most traders hear “no data yet, move on.” Shares moved about 5%, which is nothing for a stock that just opened a line to a patient population several times larger than the one currently funding the business. At $10.85 and a $3.69 billion market cap, Telix looks mispriced relative to what the pre-biopsy NDA actually represents.

Here is the number that matters: three million prostate biopsies are performed globally every year, and up to 75 percent of them come back negative. Right now Telix’s Illuccix and Gozellix PSMA-PET agents are paid to stage men who already have cancer and to find recurrence in men whose PSA is rising. The pre-biopsy setting is different. It is every man with an elevated PSA or a suspicious MRI, before a needle goes in, deciding whether a biopsy is even necessary. That is a fundamentally larger pool than “men already diagnosed.”

Reimbursement is the real story

Illuccix is already approved and reimbursed for initial staging and recurrence monitoring. Telix generated $247 million in Q2 2026 revenue, up 21 percent year over year, with the Precision Medicine business (Illuccix plus Gozellix) doing $202 million of that at 30 percent growth. The company guides to $950 million to $970 million in 2026 revenue, over $1 billion when you add the $40 million non-refundable Regeneron payment.

What the NDA pathway changes is the reimbursement question, not the science. PSMA-PET in the pre-biopsy setting is currently an off-label, inconsistently reimbursed use. An FDA approval on a new product label would give clinicians a billable, covered indication for the pre-biopsy population. That is the difference between a nice-to-have and a standard of care. The BiPASS trial itself (NCT07052214) is the first registrational study of 68Ga-PSMA-PET in the pre-biopsy setting, a prospective open-label Phase 3 that enrolled 350 patients across the U.S. and Australia.

The clinical foundation is already published

BiPASS does not exist in a vacuum. It builds on the PRIMARY study (Emmett et al., European Urology, 2021) and PRIMARY2 (Buteau et al., Lancet Oncology, 2026), which showed that combining 68Ga-PSMA-PET with MRI can reduce unnecessary biopsies by almost 50 percent without missing clinically significant prostate cancer. That is the endpoint that matters: negative-biopsy avoidance, not just detection. A diagnostic that can cut the biopsy rate in half while preserving sensitivity for real cancer is a cost saver and a patient-experience win, which is exactly what payers and urologists will adopt.

One in four men currently declines a recommended biopsy because the procedure is painful, carries infection risk, and often yields nothing. If PSMA-PET plus MRI can tell a quarter of those men “you can skip the needle,” the clinical pull is structural, not promotional.

There is a distinction worth stating plainly because it is the difference between a nice study and an approvable product. PRIMARY and PRIMARY2 were investigator-led trials that established the concept; BiPASS is the registrational study built to convert that concept into a reimbursable label. The evidence base is strong, but it is observational in origin, and observational enthusiasm has a habit of shrinking when it is forced through a prospective registrational design. That is precisely why the FDA “alignment” on the NDA pathway, rather than a finished data readout, is the real news today: it tells you the agency is willing to consider the pre-biopsy claim as its own product, not an off-label stretch.

The comp that makes Telix look cheap

The cleanest comparison is Lantheus Holdings, the other major PSMA-PET player. Lantheus’s PYLARIFY did $240.4 million in Q2 2026 revenue, down 4.1 percent year over year, and $481.3 million in the first half, down 5.3 percent. PYLARIFY is declining because it is an 18F tracer that depends on a cyclotron supply chain, which limits distribution. Telix’s gallium-68 kits run off a generator; the isotope moat is detailed in the radiopharma supply-chain piece. The structural advantage is already showing up in the numbers: Telix’s Precision Medicine business grew 30 percent while Lantheus’s PYLARIFY shrank 4 percent in the same quarter.

This is the diagnostics flywheel in action, and it is the same mechanism described for liquid biopsy names in the diagnostics stocks breakdown: publish clinical utility data, secure payer coverage, and volume compounds as ordering becomes routine. Telix has already turned the first two crank cycles on Illuccix for staging. The pre-biopsy NDA is the third cycle, and it is the largest one, because the reimbursement question is answered at the FDA, not in the urology clinic. How PET agents actually clear the FDA and get paid is a coverage question as much as a clinical one.

Now run the multiple math. Lantheus trades at $100.88 and a $6.58 billion market cap against roughly $1.53 billion of annualized revenue, about 4.3 times sales. Telix trades at $3.69 billion against about $960 million of guided 2026 revenue, about 3.8 times forward sales. So the market is paying a higher multiple for the franchise that is shrinking and a lower multiple for the one growing 30 percent. That discount only makes sense if you believe Telix’s growth is about to stall, and the pre-biopsy NDA is the clearest argument that it will not.

The Lantheus position is also muddier after its Curium deal, analyzed in the $8 billion radiopharma acquisition piece. Lantheus is diversifying into a radiopharma roll-up to offset PYLARIFY’s decline. Telix, by contrast, is extending its lead in the exact imaging market it already dominates.

The near-term catalyst stack

This is not a one-catalyst story. Telix has a PDUFA date of September 11, 2026 for Pixclara, its floretyrosine F-18 PET agent for distinguishing true glioma progression from treatment-related changes. Pixclara is a Fast Track and Orphan-designated brain imaging agent with a decision nine days out, and it is the nearer binary event.

Behind that sits Zircaix (89Zr-girentuximab), a kidney cancer imaging BLA resubmission with Breakthrough Therapy designation, plus the Regeneron collaboration announced earlier this year with its $40 million upfront payment to jointly build next-generation radiopharmaceuticals. The BiPASS data readout and NDA submission are the headline, but Pixclara on September 11 is the date on the calendar.

The risks that keep this from being a full position

The nearest risk is the Pixclara PDUFA on September 11, a genuine binary. A complete response letter there would knock the stock regardless of how good the BiPASS story is. Enrollment completion and FDA “alignment” are process milestones, not clinical results; no efficacy data was released today, and BiPASS will not report for some time. The whole thesis rests on the PRIMARY and PRIMARY2 results translating into a registrational win, and that is not guaranteed. Lantheus and other 18F competitors are not standing still either, and if a next-generation 18F tracer solves the distribution problem, Telix’s generator advantage narrows. At 3.8 times forward sales, this is not a distressed valuation, so you are paying for growth that still has to be delivered.

Verdict

Telix is a buy here, but not with both hands. The pre-biopsy market is real, it is two to three times the size of the staging and recurrence population Telix already monetizes, and the reimbursement expansion is the kind of structural change that re-rates a diagnostics franchise. The mismatch is blunt: the market is paying a premium multiple for a shrinking 18F competitor and a discount for the 68Ga franchise growing 30 percent.

Position it as a 2 to 3 percent holding, sized for the fact that the Pixclara decision lands in nine days and could swing the stock 15 to 20 percent either way before the BiPASS story even plays out. If Pixclara clears on September 11 and the pre-biopsy NDA stays on track, the re-rating toward and eventually past Lantheus’s multiple is worth roughly 20 to 30 percent upside from here. If you cannot stomach a single-digit-binary PDUFA inside two weeks, wait for the Pixclara print and buy the BiPASS thesis on the other side of it.